{"title":"Focus of the Month For Pharmacists","description":"","products":[{"product_id":"clinical-case-study-endometriosis-pain-in-a-patient-with-pericarditis","title":"Clinical Case Study - Endometriosis Pain in a Patient with Pericarditis","description":"\u003cp\u003eGina, a 32-year-old with endometriosis, seeks treatment for her gastrointestinal and pain-related symptoms. \u003c\/p\u003e\n\u003cp\u003eGina has tried a range of conventional medications and therapies, but they’ve offered little relief for her symptoms, in particular her pain which leaves her cyclically incapacitated and impacts her work as a hotel manager.\u003c\/p\u003e\n\u003cp\u003eIn this case study, we explore how Gina’s team prescribed medical cannabis products to help Gina manage her pain and reduce the impacts on her work and wellbeing.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003ePreview this module by watching the video above.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEstimated Duration: \u003c\/strong\u003e1 hour\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAccess Duration:\u003c\/strong\u003e 12 months from date of purchase\u003c\/p\u003e\n\u003ch4\u003eLearning Outcomes\u003c\/h4\u003e\n\u003cp\u003eUpon completion of this module, you’ll be able to:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExplain the pathophysiology of endometriosis  and identify common management strategies \u003c\/li\u003e\n\u003cli\u003eDiscuss the potential benefits and limitations of medical cannabis as a treatment option for common symptoms of endometriosis\u003c\/li\u003e\n\u003cli\u003eIdentify suitable candidates for medical cannabis treatment\u003c\/li\u003e\n\u003cli\u003eFacilitate clinical discussions with patients around medical cannabis as a therapeutic option in symptom management of endometriosis\u003c\/li\u003e\n\u003cli\u003eDevise treatment plans that consider patient safety and minimise risk\u003c\/li\u003e\n\u003cli\u003eOffer effective patient education and treatment advice on the therapeutic use of medical cannabis\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!----\u003e","brand":"SAGED","offers":[{"title":"Default Title","offer_id":48044643221812,"sku":"","price":39.0,"currency_code":"AUD","in_stock":true}]},{"product_id":"medical-cannabis-and-conditions-affecting-assigned-female-at-birth-and-intersex-patients-for-pharmacists","title":"Medical Cannabis and Conditions Affecting Assigned Female At Birth and Intersex People (for Pharmacists)","description":"\u003cp\u003e\u003cstrong\u003eDesigned for pharmacists\u003c\/strong\u003e, this course delves into a range of conditions that are uniquely prevalent among people assigned female at birth and intersex individuals with female reproductive organs. These conditions often go under-recognised and can profoundly affect health and quality of life. Conventional treatments sometimes fail to fully address these issues and can carry significant risks.\u003c\/p\u003e\n\u003cp\u003eWith medical cannabis emerging as a promising alternative, this course offers evidence-based insights into its potential for managing symptoms of:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEndometriosis\u003c\/li\u003e\n\u003cli\u003eDysmenorrhoea\u003c\/li\u003e\n\u003cli\u003ePolycystic Ovary Syndrome (PCOS)\u003c\/li\u003e\n\u003cli\u003ePremenstrual Dysphoric Disorder (PMDD)\u003c\/li\u003e\n\u003cli\u003ePostpartum Depression (PPD)\u003c\/li\u003e\n\u003cli\u003eBreast, ovarian, and uterine cancers\u003c\/li\u003e\n\u003cli\u003ePerimenopause and menopause\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAdditionally, it covers critical pregnancy-related contraindications for medical cannabis.\u003c\/p\u003e\n\u003cp\u003eHealthcare professionals will gain crucial knowledge and skills to expand their therapeutic toolkit, integrating both traditional and cannabis-based approaches to enhance patient outcomes.\u003c\/p\u003e\n\u003cp\u003eThis is an opportunity to stay at the forefront of medical advancements and provide innovative care options for your patients.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003ePreview this course by watching the video above.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEstimated Duration: \u003c\/strong\u003e4 hours\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAccess Duration:\u003c\/strong\u003e 12 months from date of purchase\u003c\/p\u003e\n\u003ch4\u003eLearning Outcomes\u003c\/h4\u003e\n\u003cp\u003eUpon completion of this module, you’ll be able to:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAssess when and how medical cannabis may improve treatment outcomes for IAFABP\u003c\/li\u003e\n\u003cli\u003eMake informed recommendations to patients and their doctors around medical cannabis as a treatment option\u003c\/li\u003e\n\u003cli\u003eDeliver exceptional patient-centred care by understanding your patients' experiences and exploring their options, you will be equipped to offer compassionate, professional and attentive care when your patients ask questions or come to dispense their medications\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"SAGED","offers":[{"title":"Default Title","offer_id":48120112283956,"sku":null,"price":179.0,"currency_code":"AUD","in_stock":true}]},{"product_id":"endometriosis-and-medical-cannabis","title":"Endometriosis and Medical Cannabis","description":"\u003cp\u003eEndometriosis, a condition marked by the growth of endometrial tissue outside the uterus, causes severe and debilitating symptoms, making it the leading cause of chronic pelvic pain. Affecting 1 in 9 people assigned female at birth¹, endometriosis accounted for over 3,600 emergency department visits in 2021-2022 alone². Despite its prevalence, current treatment options are often invasive and carry significant health risks.\u003c\/p\u003e\n\u003cp\u003eThis module explores the potential of medical cannabis as an alternative treatment for endometriosis, offering symptom relief with fewer side effects.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003ePreview this module by watching the video above.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEstimated Duration: \u003c\/strong\u003e1 hour\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAccess Duration:\u003c\/strong\u003e 12 months from date of purchase\u003c\/p\u003e\n\u003ch4\u003eLearning Outcomes\u003c\/h4\u003e\n\u003cp\u003eUpon completion of this module, you’ll be able to:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExplain the pathophysiology, symptomatology and effects of endometriosis\u003c\/li\u003e\n\u003cli\u003eIdentify conventional interventions for endometriosis and describe their potential strengths and drawbacks\u003c\/li\u003e\n\u003cli\u003eDiscuss medical cannabis' mechanisms of action and therapeutic potential for treating symptoms of endometriosis (e.g. pain, low mood, anxiety, sleep problems and nausea)\u003c\/li\u003e\n\u003cli\u003eIdentify considerations and risks for selecting medical cannabis products to treat endometriosis\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cem\u003eReferences\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e¹ Armour, M., Ciccia, D., Yazdani, A., Rombauts, L., Niekerk, L. V., Schubert, R., \u0026amp; Abbott, J. (2023). Endometriosis research priorities in Australia. Australian and New Zealand Journal of Obstetrics and Gynaecology ,  63 (4), 594-598. https:\/\/doi.org\/https:\/\/doi.org\/10.1111\/ajo.13699 \u003c\/p\u003e\n\u003cp\u003e² “Endometriosis, Emergency Department Presentations.” Australian Institute of Health and Welfare, 14 Dec. 2023, www.aihw.gov.au\/reports\/chronic-disease\/endometriosis-in-australia\/contents\/treatment-management\/ed-presentations. Accessed 26 June 2024.\u003c\/p\u003e","brand":"SAGED","offers":[{"title":"Default Title","offer_id":48249022775604,"sku":"","price":39.0,"currency_code":"AUD","in_stock":true}]},{"product_id":"premenstrual-dysphoric-disorder-pmdd-and-medical-cannabis","title":"Premenstrual Dysphoric Disorder (PMDD) and Medical Cannabis","description":"\u003cp\u003ePremenstrual dysphoric disorder (PMDD) is a complex and disabling condition¹ marked by cognitive, emotional, and physical symptoms in the lead-up to menstruation². Affecting an estimated 3-8% of menstruating individuals³, with 5-8% experiencing severe distress or significant impairment in daily activities⁴, PMDD remains a challenging condition to manage. Without a clear cause, current treatments focus on symptomatic control—targeting mood regulation or hormonal balance—though many patients find limited relief.\u003c\/p\u003e\n\u003cp\u003eThis module explores the potential of medical cannabis as a therapeutic option for resistant PMDD symptoms, offering a non-hormonal alternative to traditional treatments that may carry reproductive side effects.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003ePreview this module by watching the video above.\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEstimated Duration: \u003c\/strong\u003e1 hour\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAccess Duration:\u003c\/strong\u003e 12 months from date of purchase\u003c\/p\u003e\n\u003ch4\u003eLearning Outcomes\u003c\/h4\u003e\n\u003cp\u003eUpon completion of this module, you’ll be able to:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExplain the pathophysiology, symptomatology and effects of PMDD\u003c\/li\u003e\n\u003cli\u003eIdentify conventional interventions for PMDD and describe their potential strengths and drawbacks\u003c\/li\u003e\n\u003cli\u003eDiscuss medical cannabis' mechanisms of action and therapeutic potential for treating symptoms of PMDD (e.g. pain, low mood, anxiety and sleep problems)\u003c\/li\u003e\n\u003cli\u003eIdentify considerations and risks for selecting medical cannabis products to treat PMDD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cem\u003eReferences\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003e¹ Osborn, Elizabeth, et al. “Women’s Experiences of Receiving a Diagnosis of Premenstrual Dysphoric Disorder: A Qualitative Investigation.” BMC Women’s Health, vol. 20, no. 1, Oct. 2020, https:\/\/doi.org\/10.1186\/s12905-020-01100-8. Accessed 26 June 2024.\u003c\/p\u003e\n\u003cp\u003e² Hantsoo, Liisa, and C. Neill Epperson. “Premenstrual Dysphoric Disorder: Epidemiology and Treatment.” Current Psychiatry Reports, vol. 17, 2015, https:\/\/doi.org\/10.1007\/s11920-015-0628-3. Accessed 26 June 2024.\u003c\/p\u003e\n\u003cp\u003e³ Halbreich, Uriel, et al. “The Prevalence, Impairment, Impact, and Burden of Premenstrual Dysphoric Disorder (PMS\/PMDD).” Psychoneuroendocrinology, vol. 28, no. 3, Aug. 2003, pp. 1–23, https:\/\/doi.org\/10.1016\/s0306-4530(03)00098-2. Accessed 26 June 2024.\u003c\/p\u003e\n\u003cp\u003e⁴ Slavin, Melissa, et al. “Cannabis and Symptoms of PMS and PMDD.” Addiction Research \u0026amp; Theory, vol. 25, no. 5, Mar. 2017, pp. 383–89, https:\/\/doi.org\/10.1080\/16066359.2017.1294165. Accessed 26 June 2024.\u003c\/p\u003e","brand":"SAGED","offers":[{"title":"Default Title","offer_id":48249108693300,"sku":"","price":39.0,"currency_code":"AUD","in_stock":true}]}],"url":"https:\/\/saged.com.au\/collections\/focus-of-the-month-for-doctors-copy.oembed","provider":"SAGED","version":"1.0","type":"link"}